 Warren Capell
Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rivaroxaban | 16 | 2026 | 268 | 2.500 |
Why?
| | Peripheral Arterial Disease | 17 | 2026 | 504 | 2.040 |
Why?
| | Aspirin | 14 | 2026 | 402 | 1.700 |
Why?
| | Factor Xa Inhibitors | 9 | 2026 | 187 | 1.640 |
Why?
| | Lower Extremity | 13 | 2026 | 440 | 1.420 |
Why?
| | Endovascular Procedures | 6 | 2026 | 385 | 0.940 |
Why?
| | Platelet Aggregation Inhibitors | 12 | 2026 | 496 | 0.910 |
Why?
| | Beneficence | 1 | 2021 | 20 | 0.660 |
Why?
| | Research Subjects | 1 | 2021 | 39 | 0.650 |
Why?
| | Hypertriglyceridemia | 3 | 2006 | 44 | 0.650 |
Why?
| | Personal Autonomy | 1 | 2021 | 59 | 0.630 |
Why?
| | Thrombosis | 2 | 2022 | 396 | 0.630 |
Why?
| | Informed Consent | 2 | 2021 | 197 | 0.610 |
Why?
| | Ischemia | 6 | 2024 | 422 | 0.600 |
Why?
| | Patient Selection | 2 | 2021 | 727 | 0.580 |
Why?
| | Outpatients | 1 | 2021 | 447 | 0.510 |
Why?
| | Double-Blind Method | 9 | 2026 | 2033 | 0.430 |
Why?
| | Drug Therapy, Combination | 9 | 2026 | 1044 | 0.420 |
Why?
| | Venous Thromboembolism | 3 | 2023 | 326 | 0.400 |
Why?
| | Vascular Surgical Procedures | 4 | 2026 | 343 | 0.400 |
Why?
| | Lipoprotein Lipase | 2 | 2010 | 56 | 0.360 |
Why?
| | Lipoproteins | 4 | 2010 | 165 | 0.350 |
Why?
| | Hospitalization | 2 | 2021 | 2446 | 0.330 |
Why?
| | Risk Assessment | 1 | 2021 | 3729 | 0.330 |
Why?
| | Hypolipidemic Agents | 3 | 2006 | 89 | 0.330 |
Why?
| | Fat Emulsions, Intravenous | 1 | 2010 | 29 | 0.320 |
Why?
| | Clinical Trials, Phase III as Topic | 2 | 2021 | 116 | 0.300 |
Why?
| | Multicenter Studies as Topic | 3 | 2021 | 408 | 0.290 |
Why?
| | Hemorrhage | 6 | 2026 | 813 | 0.280 |
Why?
| | Coronary Artery Disease | 2 | 2024 | 743 | 0.260 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2024 | 1742 | 0.250 |
Why?
| | Triglycerides | 3 | 2010 | 517 | 0.240 |
Why?
| | Euthyroid Sick Syndromes | 1 | 2026 | 6 | 0.240 |
Why?
| | Thyrotropin | 1 | 2026 | 119 | 0.230 |
Why?
| | Thyroid Gland | 1 | 2026 | 88 | 0.230 |
Why?
| | Glucose | 1 | 2010 | 1033 | 0.220 |
Why?
| | Middle Aged | 18 | 2026 | 35971 | 0.210 |
Why?
| | Myocardial Infarction | 2 | 2022 | 1209 | 0.200 |
Why?
| | Male | 24 | 2026 | 72431 | 0.200 |
Why?
| | Treatment Outcome | 10 | 2026 | 11735 | 0.200 |
Why?
| | Fatty Acids, Nonesterified | 3 | 2010 | 154 | 0.190 |
Why?
| | Fenofibrate | 1 | 2003 | 28 | 0.190 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2023 | 92 | 0.190 |
Why?
| | Antifibrinolytic Agents | 1 | 2023 | 63 | 0.180 |
Why?
| | Female | 22 | 2026 | 78304 | 0.180 |
Why?
| | Humans | 33 | 2026 | 144667 | 0.180 |
Why?
| | Muscle, Skeletal | 2 | 2010 | 1788 | 0.180 |
Why?
| | Drug-Eluting Stents | 1 | 2021 | 88 | 0.170 |
Why?
| | Blood Coagulation Disorders | 1 | 2023 | 196 | 0.170 |
Why?
| | Placebos | 1 | 2021 | 193 | 0.160 |
Why?
| | Paclitaxel | 1 | 2021 | 256 | 0.160 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2021 | 133 | 0.160 |
Why?
| | Postoperative Complications | 2 | 2024 | 2950 | 0.160 |
Why?
| | Extremities | 1 | 2021 | 140 | 0.150 |
Why?
| | Clinical Trials as Topic | 3 | 2021 | 1056 | 0.150 |
Why?
| | Follow-Up Studies | 2 | 2021 | 5414 | 0.150 |
Why?
| | Vasodilation | 1 | 2003 | 520 | 0.150 |
Why?
| | Aged | 13 | 2026 | 25955 | 0.140 |
Why?
| | Cause of Death | 1 | 2021 | 464 | 0.140 |
Why?
| | Subacute Care | 1 | 2019 | 82 | 0.140 |
Why?
| | Brain Ischemia | 1 | 2021 | 358 | 0.130 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2021 | 2019 | 0.130 |
Why?
| | Purinergic P2Y Receptor Antagonists | 1 | 2018 | 71 | 0.130 |
Why?
| | Nursing Homes | 1 | 2019 | 173 | 0.130 |
Why?
| | Health Services Research | 1 | 2019 | 392 | 0.120 |
Why?
| | Hospital Mortality | 1 | 2021 | 1033 | 0.120 |
Why?
| | Lipoproteins, LDL | 1 | 1996 | 119 | 0.120 |
Why?
| | Skilled Nursing Facilities | 1 | 2017 | 151 | 0.110 |
Why?
| | Fibrinolytic Agents | 1 | 2017 | 290 | 0.110 |
Why?
| | Insulin Resistance | 3 | 2013 | 1241 | 0.110 |
Why?
| | Ethics, Research | 1 | 2014 | 33 | 0.100 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2024 | 2573 | 0.100 |
Why?
| | Disease Management | 1 | 2017 | 650 | 0.100 |
Why?
| | Anticoagulants | 3 | 2023 | 729 | 0.090 |
Why?
| | Societies, Medical | 1 | 2017 | 890 | 0.090 |
Why?
| | Caspase 1 | 1 | 2013 | 146 | 0.090 |
Why?
| | Stroke | 1 | 2021 | 1262 | 0.090 |
Why?
| | Cardiovascular Diseases | 2 | 2021 | 2172 | 0.090 |
Why?
| | Interleukin-18 | 1 | 2013 | 234 | 0.090 |
Why?
| | Heparin | 2 | 2023 | 243 | 0.080 |
Why?
| | Interleukin-1beta | 1 | 2013 | 390 | 0.080 |
Why?
| | Research Design | 1 | 2017 | 1129 | 0.080 |
Why?
| | Arteries | 2 | 2022 | 258 | 0.080 |
Why?
| | Biomedical Research | 1 | 2017 | 712 | 0.080 |
Why?
| | Transfection | 2 | 2010 | 924 | 0.080 |
Why?
| | Lactones | 1 | 2010 | 59 | 0.080 |
Why?
| | Dietary Fats | 2 | 2010 | 308 | 0.080 |
Why?
| | Myoblasts | 1 | 2010 | 83 | 0.080 |
Why?
| | Diet, Carbohydrate-Restricted | 1 | 2010 | 37 | 0.080 |
Why?
| | Diet, Fat-Restricted | 2 | 2010 | 79 | 0.080 |
Why?
| | Hypercholesterolemia | 1 | 2010 | 93 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 2 | 2021 | 967 | 0.070 |
Why?
| | Obesity | 2 | 2013 | 3070 | 0.070 |
Why?
| | Blotting, Western | 1 | 2010 | 1161 | 0.070 |
Why?
| | Inflammation | 2 | 2023 | 2870 | 0.060 |
Why?
| | Simvastatin | 1 | 2006 | 59 | 0.060 |
Why?
| | Thyroid Function Tests | 1 | 2026 | 19 | 0.060 |
Why?
| | Triiodothyronine | 1 | 2026 | 54 | 0.060 |
Why?
| | Thyroxine | 1 | 2026 | 65 | 0.060 |
Why?
| | Temperance | 1 | 2005 | 20 | 0.060 |
Why?
| | Limb Salvage | 1 | 2026 | 73 | 0.060 |
Why?
| | Palliative Care | 1 | 2014 | 1011 | 0.060 |
Why?
| | Adult | 5 | 2021 | 40489 | 0.050 |
Why?
| | Anticholesteremic Agents | 1 | 2006 | 154 | 0.050 |
Why?
| | Cell Line | 1 | 2010 | 2821 | 0.050 |
Why?
| | Treatment Failure | 1 | 2005 | 365 | 0.050 |
Why?
| | Cross-Over Studies | 2 | 2006 | 605 | 0.050 |
Why?
| | Practice Guidelines as Topic | 2 | 2017 | 1569 | 0.050 |
Why?
| | C-Reactive Protein | 1 | 2006 | 420 | 0.050 |
Why?
| | Weight Loss | 1 | 2010 | 839 | 0.050 |
Why?
| | Incidence | 2 | 2021 | 2892 | 0.050 |
Why?
| | Risk Factors | 3 | 2026 | 10796 | 0.050 |
Why?
| | Thromboplastin | 1 | 2023 | 64 | 0.050 |
Why?
| | Angiography | 1 | 2024 | 208 | 0.050 |
Why?
| | Heart Failure | 1 | 2017 | 2324 | 0.050 |
Why?
| | Aged, 80 and over | 2 | 2026 | 8284 | 0.050 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 438 | 0.050 |
Why?
| | Vesicular Transport Proteins | 1 | 2003 | 85 | 0.050 |
Why?
| | Forearm | 1 | 2003 | 140 | 0.050 |
Why?
| | Numbers Needed To Treat | 1 | 2021 | 7 | 0.040 |
Why?
| | Metabolic Syndrome | 1 | 2005 | 354 | 0.040 |
Why?
| | Prospective Studies | 2 | 2026 | 7994 | 0.040 |
Why?
| | Fasting | 1 | 2003 | 275 | 0.040 |
Why?
| | Frailty | 1 | 2024 | 200 | 0.040 |
Why?
| | Regional Blood Flow | 1 | 2003 | 513 | 0.040 |
Why?
| | Postmenopause | 1 | 2003 | 390 | 0.040 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2021 | 176 | 0.040 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2003 | 441 | 0.040 |
Why?
| | Atherosclerosis | 1 | 2024 | 409 | 0.040 |
Why?
| | Internationality | 1 | 2020 | 154 | 0.040 |
Why?
| | Time Factors | 2 | 2026 | 7140 | 0.040 |
Why?
| | Lipid Metabolism | 1 | 2003 | 524 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2003 | 590 | 0.040 |
Why?
| | Confidentiality | 1 | 2019 | 80 | 0.040 |
Why?
| | Acute Disease | 1 | 2021 | 1029 | 0.030 |
Why?
| | Alcohol Drinking | 1 | 2005 | 827 | 0.030 |
Why?
| | Mice | 3 | 2013 | 18261 | 0.030 |
Why?
| | Algorithms | 1 | 2006 | 1844 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2021 | 1322 | 0.030 |
Why?
| | Global Health | 1 | 2021 | 401 | 0.030 |
Why?
| | Proteins | 1 | 2003 | 1016 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1268 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2003 | 1159 | 0.030 |
Why?
| | Arteriosclerosis | 1 | 1996 | 83 | 0.030 |
Why?
| | Cholesterol, LDL | 2 | 2010 | 359 | 0.030 |
Why?
| | Patient Safety | 1 | 2019 | 353 | 0.030 |
Why?
| | Particle Size | 1 | 1996 | 401 | 0.030 |
Why?
| | Reference Values | 1 | 1996 | 794 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 1996 | 342 | 0.030 |
Why?
| | Ethics Committees, Research | 1 | 2014 | 40 | 0.030 |
Why?
| | Patient Transfer | 1 | 2017 | 208 | 0.030 |
Why?
| | Animals | 3 | 2013 | 37948 | 0.020 |
Why?
| | Research Personnel | 1 | 2014 | 185 | 0.020 |
Why?
| | Diet, High-Fat | 1 | 2013 | 261 | 0.020 |
Why?
| | Cohort Studies | 1 | 2022 | 5957 | 0.020 |
Why?
| | Diet, Reducing | 1 | 2010 | 91 | 0.020 |
Why?
| | Dietary Carbohydrates | 1 | 2010 | 147 | 0.020 |
Why?
| | Body Weight | 1 | 2013 | 968 | 0.020 |
Why?
| | Quality Improvement | 1 | 2017 | 1287 | 0.020 |
Why?
| | Phenotype | 1 | 1996 | 3147 | 0.020 |
Why?
| | Communication | 1 | 2014 | 972 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 2104 | 0.020 |
Why?
| | Energy Intake | 1 | 2010 | 501 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2013 | 3109 | 0.010 |
Why?
| | Dyslipidemias | 1 | 2006 | 182 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2003 | 17149 | 0.010 |
Why?
| | Munc18 Proteins | 1 | 2003 | 24 | 0.010 |
Why?
| | SNARE Proteins | 1 | 2003 | 40 | 0.010 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2003 | 214 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2003 | 751 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 973 | 0.010 |
Why?
| | Insulin | 1 | 2010 | 2502 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2003 | 2184 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2003 | 4110 | 0.010 |
Why?
| | Blood Glucose | 1 | 2003 | 2326 | 0.010 |
Why?
|
|
Capell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|